These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 28515944)

  • 1. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
    Gnjatic S; Bronte V; Brunet LR; Butler MO; Disis ML; Galon J; Hakansson LG; Hanks BA; Karanikas V; Khleif SN; Kirkwood JM; Miller LD; Schendel DJ; Tanneau I; Wigginton JM; Butterfield LH
    J Immunother Cancer; 2017; 5():44. PubMed ID: 28515944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.
    Butterfield LH
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):12-15. PubMed ID: 28943324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic evaluation of immune regulation and modulation.
    Stroncek DF; Butterfield LH; Cannarile MA; Dhodapkar MV; Greten TF; Grivel JC; Kaufman DR; Kong HH; Korangy F; Lee PP; Marincola F; Rutella S; Siebert JC; Trinchieri G; Seliger B
    J Immunother Cancer; 2017; 5():21. PubMed ID: 28331613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Immunotherapy: Current Developments and Challenges.
    Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.
    Gulley JL; Repasky EA; Wood LS; Butterfield LH
    J Immunother Cancer; 2017 Jul; 5(1):55. PubMed ID: 28716068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDSC; the Most Important Cell You Have Never Heard Of.
    Tesi RJ
    Trends Pharmacol Sci; 2019 Jan; 40(1):4-7. PubMed ID: 30527590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
    Bedognetti D; Ceccarelli M; Galluzzi L; Lu R; Palucka K; Samayoa J; Spranger S; Warren S; Wong KK; Ziv E; Chowell D; Coussens LM; De Carvalho DD; DeNardo DG; Galon J; Kaufman HL; Kirchhoff T; Lotze MT; Luke JJ; Minn AJ; Politi K; Shultz LD; Simon R; Thórsson V; Weidhaas JB; Ascierto ML; Ascierto PA; Barnes JM; Barsan V; Bommareddy PK; Bot A; Church SE; Ciliberto G; De Maria A; Draganov D; Ho WS; McGee HM; Monette A; Murphy JF; Nisticò P; Park W; Patel M; Quigley M; Radvanyi L; Raftopoulos H; Rudqvist NP; Snyder A; Sweis RF; Valpione S; Zappasodi R; Butterfield LH; Disis ML; Fox BA; Cesano A; Marincola FM;
    J Immunother Cancer; 2019 May; 7(1):131. PubMed ID: 31113486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy biomarkers 2016: overcoming the barriers.
    Gulley JL; Berzofsky JA; Butler MO; Cesano A; Fox BA; Gnjatic S; Janetzki S; Kalavar S; Karanikas V; Khleif SN; Kirsch I; Lee PP; Maccalli C; Maecker H; Schlom J; Seliger B; Siebert J; Stroncek DF; Thurin M; Yuan J; Butterfield LH
    J Immunother Cancer; 2017 Mar; 5(1):29. PubMed ID: 28653584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
    Nixon AB; Schalper KA; Jacobs I; Potluri S; Wang IM; Fleener C
    J Immunother Cancer; 2019 Nov; 7(1):325. PubMed ID: 31775882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].
    Kaplon H; Dieu-Nosjean MC
    Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
    Yuan J; Hegde PS; Clynes R; Foukas PG; Harari A; Kleen TO; Kvistborg P; Maccalli C; Maecker HT; Page DB; Robins H; Song W; Stack EC; Wang E; Whiteside TL; Zhao Y; Zwierzina H; Butterfield LH; Fox BA
    J Immunother Cancer; 2016; 4():3. PubMed ID: 26788324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
    Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
    Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Top 10 Challenges in Cancer Immunotherapy.
    Hegde PS; Chen DS
    Immunity; 2020 Jan; 52(1):17-35. PubMed ID: 31940268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer immunotherapy: where are we and where are we going?
    De Velasco MA; Uemura H
    Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immuno-oncology-101: overview of major concepts and translational perspectives.
    Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
    Li X; Shao C; Shi Y; Han W
    J Hematol Oncol; 2018 Feb; 11(1):31. PubMed ID: 29482595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor inherent interferons: Impact on immune reactivity and immunotherapy.
    Brockwell NK; Parker BS
    Cytokine; 2019 Jun; 118():42-47. PubMed ID: 29681426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.